This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Glucagon-like peptide 1 (GLP-1)	<p>Mouse studies suggest a GLP-1 cleavage product could help treat AD. In brain slices from an AD mouse model, pretreatment with the GLP-1 cleavage product GLP-1(9-36)^{amide} restored hippocampal synaptic plasticity and normalized levels of mitochondria-derived superoxide, which is elevated by β-amyloid (Aβ). In a mouse model of AD, GLP-1(9-36)^{amide} decreased learning and memory deficits compared with vehicle control without altering amyloid precursor protein (APP) or Aβ levels. Next steps could include testing GLP-1(9-36)^{amide} in additional animal models of AD.</p> <p><i>SciBX</i> 5(41); doi:10.1038/scibx.2012.1090 Published online Oct. 18, 2012</p>	Patent and licensing status unavailable	<p>Ma, T. <i>et al. J. Neurosci.</i>; published online Oct. 3, 2012; doi:10.1523/JNEUROSCI.2107-12.2012 Contact: Eric Klann, New York University, New York, N.Y. e-mail: eklann@cns.nyu.edu</p>